A trial of special immune cells for viral infections after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant.
- You have a current viral infection (CMV, EBV, or another listed virus) that did not improve after at least 2 weeks of usual treatment.
- Your donor cells are available for this treatment.
- Your liver, kidneys, heart, and lungs are working well enough to participate.
- You or your guardian can understand and agree to the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of donor immune cell (depleted of CD45RA cells) to see if it can prevent serious viral infections in people at high risk after a stem cell transplant from a half-matched donor.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial tests a special type of donor immune cell infusion (called DLI) that has been processed to remove certain cells that might limit its effectiveness. It is for people whose blood cancer has come back after a stem cell transplant and who have not responded well to standard donor cell treatments.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.